Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Multi-Cancer Early Detection Test Is Sensitive and Accurate in Detecting Shared DNA Methylation Signal in a Variety of Lymphoid and Plasma Cell Neoplasms

Candace Westgate, Gilles Salles, Stephannie Shih, Margarita Lopatin, Kathryn N. Kurtzman, Katerina Kappes, Oliver Venn, Samir Parekh, Jeffrey M. Venstrom, Anas Younes, Rita Shaknovich

Blood (2023) 142 (Supplement 1): 3646.

https://doi.org/10.1182/blood-2023-186481

Published: 2023

Journal Articles

Treatment dependence of prognostic gene expression signatures in de novo follicular lymphoma

Christopher R. Bolen, Federico Mattiello, Michael Herold, Wolfgang Hiddemann, Sarah Huet, Wolfram Klapper, Robert Marcus, Farheen Mir, Gilles Salles, Oliver Weigert, Tina Nielsen, Mikkel Z. Oestergaard, Jeffrey M. Venstrom

Blood (2021) 137 (19): 2704–2707.

https://doi.org/10.1182/blood.2020008119

Published: 2021

Includes: Supplemental data

Journal Articles

Neoantigens in Patients with De Novo Follicular Lymphoma: Results from the PRIMA Study

Carsten Henneges, Dexter X Jin, Jeffrey M Venstrom, Sally E Trabucco, PhD, Tina G Nielsen, Elicia M. Penuel, Sarah Huet, Gilles Salles, MD PhD, Joseph N Paulson

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-134795

Published: 2020

Journal Articles

Dynamics of Activated CD8+ T-cells and Decreased Osteoclasts in the Tumor Microenvironment are Associated with Clinical Efficacy of Anti-PD-L1 and Anti-CD38 Combination Treatment in Relapsed or Refractory Multiple Myeloma

Aparna Raval, PhD, Hearn Jay Cho, MD PhD, Cherie Green, BS, Elisabeth Wassner Fritsch, PharmD, Connie Ma, MS, Naomi Chang, MSc, Mark Yan, PhD, Mark Kockx, MD PhD, Shine Shen, MS, Ling-Yuh Huw, PhD, Emily Balestiere, BA, Marina Lipkind, BS, Huang Huang, MSc, Michelle Byrtek, PhD, Dawn Colburn, PharmD, BCOP, Sandy W. Wong, Jeffrey M. Venstrom, MD PhD, Joanne I Adamkewicz, PhD

Blood (2019) 134 (Supplement_1): 1907.

https://doi.org/10.1182/blood-2019-123652

Published: 2019

Journal Articles

Recapitulation of Prognostic Mutational Subtyping Utilizing F1H in GOYA and CAVALLI and the Potential to Highlight Benefit of Targeted Therapy in De Novo DLBCL

Eugene C Kim, PhD, Jinzhen Fan, PhD, Christopher R Bolen, PhD, Alexandra Bazeos, MD PhD FRCPath, Yanwen Jiang, PhD, Sandhya Balasubramanian, MS, Rama Balakrishnan, PhD, Andrea Knapp, PhD, Kathryn Humphrey, BSc, Tina G Nielsen, MD PhD, Jeffrey M. Venstrom, MD PhD, Genevive Hernandez, PhD, Joseph N Paulson, PhD

Blood (2019) 134 (Supplement_1): 2788.

https://doi.org/10.1182/blood-2019-124687

Published: 2019

Journal Articles

Molecular Characteristics and Disease Burden Metrics Determined By Next-Generation Sequencing on Circulating Tumor DNA Correlate with Progression Free Survival in Previously Untreated Diffuse Large B-Cell Lymphoma

Ehsan Tabari, PhD, Alexander F Lovejoy, PhD, Hai Lin, PhD, Christopher R Bolen, PhD, Seng Lor Saelee, BA, Joshua P Lefkowitz, David M. Kurtz, MD PhD, Patrik Vitazka, MD PhD, Jeffrey M. Venstrom, MD PhD, Tina G Nielsen, MD PhD, Joana M Parreira, MD, Daniel M Klass, PhD, Khai T Luong, PhD

Blood (2019) 134 (Supplement_1): 490.

https://doi.org/10.1182/blood-2019-123633

Published: 2019

Journal Articles

A Simulation Analysis to Evaluate the Effect of Prospective Biomarker Testing on Progression-Free Survival (PFS) in DLBCL

Edith Szafer-Glusman, Juan Liu, Franklin V. Peale, Jr., Thalia A. Farazi, Jill Ray, Carsten Horn, Mikkel Z. Oestergaard, Martin Kornacker, Laurie H. Sehn, MDMPH, Günter Fingerle-Rowson, Jeffrey M. Venstrom, Michelle Byrtek, Elizabeth Punnoose

Blood (2017) 130 (Supplement 1): 419.

https://doi.org/10.1182/blood.V130.Suppl_1.419.419

Published: 2017

Journal Articles

Evidence of Targetable Immune Dysfunction in the Bone Marrow of Patients with Intermediate/High-Risk Myelodysplastic Syndrome Refractory to Hypomethylating Agents

Cherie Green, Mark Yan, Stefani Nalle, Connie Ma, Alberto Robert, Judy Zhong, Kartik Krishnan, Patrick Phuong, PharmD, John Byon, Paul Woodard, Michael J. Nemeth, PhD, Elizabeth A. Griffiths, MD, Joanne I. Adamkewicz, Jeffrey M. Venstrom, Monique Dail

Blood (2017) 130 (Supplement 1): 4241.

https://doi.org/10.1182/blood.V130.Suppl_1.4241.4241

Published: 2017

Journal Articles

Low Peripheral Blood NK Cell Count Is Associated with Worse Clinical Outcome in Patients with Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Immunochemotherapy: Results from the Frontline Phase 3 GALLIUM and GOYA Trials

Magdalena Klanova, MD, Mikkel Z. Oestergaard, Marek Trněný, MD PhD, Wolfgang Hiddemann, MD PhD, Robert Marcus, Laurie H. Sehn, MDMPH, Umberto Vitolo, MD, Alexandra Bazeos, Valentin Goede, MD, Harald Zeuner, Andrea Knapp, Denis Sahin, Nathalie Danesi, Christopher Bolen, Susan Robson, Jeffrey M. Venstrom, Tina Nielsen, Günter Fingerle-Rowson

Blood (2017) 130 (Supplement 1): 727.

https://doi.org/10.1182/blood.V130.Suppl_1.727.727

Published: 2017

Journal Articles

High Expression of Programmed Death-Ligand 1 (PD-L1) Correlates with Macrophage Gene Expression and Is Associated with Prolonged Progression-Free Survival (PFS) in Patients (pts) with First-Line (1L) Diffuse Large B-Cell Lymphoma (DLBCL)

Ronald McCord, Christopher Bolen, Hartmut Koeppen, Edward E. Kadel, III, Günter Fingerle-Rowson, Mikkel Z. Oestergaard, Jeffrey M. Venstrom

Blood (2017) 130 (Supplement 1): 195.

https://doi.org/10.1182/blood.V130.Suppl_1.195.195

Published: 2017

Journal Articles

Distinct Patterns of PD-L1 and PD-L2 Expression By Tumor and Non-Tumor Cells in Patients with MM, MDS and AML

Monique Dail, Long Yang, Cherie Green, Connie Ma, Alberto Robert, Edward E. Kadel, Harmut Koeppen, Joanne Adamkewicz, John Byon, Joseph Woodard, Scott J Rodig, Jeffrey M Venstrom

Blood (2016) 128 (22): 1340.

https://doi.org/10.1182/blood.V128.22.1340.1340

Published: 2016

Journal Articles

A Favorable BCL-2 Family Expression Profile May Explain the Increased Susceptibility of the t(11;14) Multiple Myeloma Subgroup to Single Agent Venetoclax

Jenny Wu, Jeremy Ross, Franklin V. Peale, Jr., John D Shaughnessy, Jr., PhD, Ryan K Van Laar, PhD, Gareth J Morgan, MD PhD, Jeffrey M Venstrom, Elizabeth A. Punnoose, PhD

Blood (2016) 128 (22): 5613.

https://doi.org/10.1182/blood.V128.22.5613.5613

Published: 2016

Journal Articles

Tigit, CD226 and PD-L1/PD-1 Are Highly Expressed By Marrow-Infiltrating T Cells in Patients with Multiple Myeloma

Mahesh Yadav, Cherie Green, Connie Ma, Alberto Robert, Andrew Glibicky, Rin Nakamura, Teiko Sumiyoshi, Ray Meng, Yu-Waye Chu, Jenny Wu, John Byon, Joseph Woodard, Joanne Adamkewicz, Jane Grogan, Jeffrey M. Venstrom

Blood (2016) 128 (22): 2102.

https://doi.org/10.1182/blood.V128.22.2102.2102

Published: 2016

Journal Articles

Minimal Residual Disease (MRD) Assessment By Multiparametric Flow Cytometry Is Prognostic for Progression-Free Survival in Phase 1/1b Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients Treated with Idasanutlin MDM2 Antagonist

Benjamin Lanza, Giovanni Martinelli, Karen W.L. Yee, MD, Lori Jukofsky, Bernhard Reis, PhD, Steven Blotner, PhD, Mark W. Drummond, PhDMD, Norbert Vey, MD PhD, Karen Seiter, MD, Michael J. Dickinson, MBBS, FRACP, FRCPA, Kevin R. Kelly, MD PhD, Margaret Kasner, MD, Michel Theron, PhD, Jeffrey M. Venstrom, Steven Middleton, PhD, Lin-Chi Chen, MD PhD, Nelson Kinnersley, Gwen Nichols, MD, William E. Pierceall, PhD

Blood (2016) 128 (22): 2843.

https://doi.org/10.1182/blood.V128.22.2843.2843

Published: 2016

Journal Articles

Mutation Load and a Functional T Effector Signature May Distinguish Immunologically Distinct and Clinically Relevant Lymphoma Subsets

Chris Bolen, PhD, Ronald McCord, PhD, Garrett Frampton, PhD, Richard Bourgon, PhD, Elizabeth A. Punnoose, PhD, Edith Szafer-Glusman, PhD, Pierre Sujobert, MD PhD, Luc Xerri, MD PhD, Sarah Huet, PharmD, PhD, Gilles Salles, MD PhD, Jeffrey M Venstrom

Blood (2016) 128 (22): 913.

https://doi.org/10.1182/blood.V128.22.913.913

Published: 2016

Journal Articles

Safety and Clinical Activity of Atezolizumab (Anti-PDL1) in Combination with Obinutuzumab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Brian G. Till, MD, Steven I. Park, MD, Leslie L. Popplewell, MD, Andre Goy, MD, Elicia Penuel, PhD, Jeffrey M Venstrom, MD, Bo Liu, Guenter Fingerle-Rowson, MD PhD, John Byon, MD PhD, Paul Woodard, MD, M. Lia Palomba, MD

Blood (2015) 126 (23): 5104.

https://doi.org/10.1182/blood.V126.23.5104.5104

Published: 2015

Journal Articles

KIR and HLA Genotypes Influence Clinical Outcome in Multiple Myeloma Patients Treated with SAR650984 (Anti-CD38) in Combination with Lenalidomide and Dexamethasone

John Marra, BS, Juan Du, MD PhD, Jimmy Hwang, PhD, Jeffrey L Wolf, MD, Thomas G. Martin, MD, Jeffrey M Venstrom, MD

Blood (2014) 124 (21): 2126.

https://doi.org/10.1182/blood.V124.21.2126.2126

Published: 2014

Journal Articles

Delayed Hematopoietic Recovery After Autologous Stem Cell Transplantation In Patients Receiving Arsenic Trioxide-Based Therapy For Acute Promyelocytic Leukemia

Gabriel N. Mannis, MD, Lloyd E Damon, MD, Weiyun Z. Ai, MD, PhD, Charalambos Andreadis, MD, MS, Karin ML Gaensler, MD, Neel K. Gupta, M.D., Lawrence D. Kaplan, M.D., Andrew D. Leavitt, MD, Aaron C. Logan, MD, PhD, Rebecca L. Olin, MD, MS, Peter H. Sayre, MD, PhD, Catherine C Smith, MD, Jeffrey M Venstrom, MD, Thomas G Martin, III, MD

Blood (2013) 122 (21): 2172.

https://doi.org/10.1182/blood.V122.21.2172.2172

Published: 2013

Journal Articles

Natural Killer Cell Licensing Delineates NK “Helper/Repair” and NK “Effector/Suppressor” Subsets During Viral Infections

Can M. Sungur, Anthony E. Zamora, Ethan G. Aguilar, Yajarayma Tang-Feldman, Juan Du, Nicole Baumgarth, Mingyi Chen, MD, PhD, Claire Pomeroy, Jeffrey M. Venstrom, MD, William J. Murphy, PhD

Blood (2013) 122 (21): 13.

https://doi.org/10.1182/blood.V122.21.13.13

Published: 2013

Journal Articles

Donor KIR3DL1 and HLA-B Allotypes Control Leukemia Relapse After Allogeneic Hematopoietic Stem Cell Transplantation

Fabio Giglio, MD, Ted A. Gooley, PhD, Jeffrey M Venstrom, MD, Meighan M Gallagher, LiHua Hou, PhD, Carolyn K Hurley, PhD, Tatiana Lebedeva, MD, PhD, Harriet Noreen, CHS, Raja Rajalingam, PhD, Elaine F Reed, PhD, Neng Yu, MD, Cynthia Vierra-Green, MS, Michael D Haagenson, MS, Mari Malkki, PhD, Effie W. Petersdorf, MD, Stephen Spellman, MBS, Katharine C. Hsu, MD, PhD

Blood (2012) 120 (21): 349.

https://doi.org/10.1182/blood.V120.21.349.349

Published: 2012

NARROW

Multi-Cancer Early Detection Test Is Sensitive and Accurate in Detecting Shared DNA Methylation Signal in a Variety of Lymphoid and Plasma Cell Neoplasms

Treatment dependence of prognostic gene expression signatures in de novo follicular lymphoma

Neoantigens in Patients with De Novo Follicular Lymphoma: Results from the PRIMA Study

Dynamics of Activated CD8+ T-cells and Decreased Osteoclasts in the Tumor Microenvironment are Associated with Clinical Efficacy of Anti-PD-L1 and Anti-CD38 Combination Treatment in Relapsed or Refractory Multiple Myeloma

Recapitulation of Prognostic Mutational Subtyping Utilizing F1H in GOYA and CAVALLI and the Potential to Highlight Benefit of Targeted Therapy in De Novo DLBCL

Molecular Characteristics and Disease Burden Metrics Determined By Next-Generation Sequencing on Circulating Tumor DNA Correlate with Progression Free Survival in Previously Untreated Diffuse Large B-Cell Lymphoma

A Simulation Analysis to Evaluate the Effect of Prospective Biomarker Testing on Progression-Free Survival (PFS) in DLBCL

Evidence of Targetable Immune Dysfunction in the Bone Marrow of Patients with Intermediate/High-Risk Myelodysplastic Syndrome Refractory to Hypomethylating Agents

Low Peripheral Blood NK Cell Count Is Associated with Worse Clinical Outcome in Patients with Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Immunochemotherapy: Results from the Frontline Phase 3 GALLIUM and GOYA Trials

High Expression of Programmed Death-Ligand 1 (PD-L1) Correlates with Macrophage Gene Expression and Is Associated with Prolonged Progression-Free Survival (PFS) in Patients (pts) with First-Line (1L) Diffuse Large B-Cell Lymphoma (DLBCL)

Distinct Patterns of PD-L1 and PD-L2 Expression By Tumor and Non-Tumor Cells in Patients with MM, MDS and AML

A Favorable BCL-2 Family Expression Profile May Explain the Increased Susceptibility of the t(11;14) Multiple Myeloma Subgroup to Single Agent Venetoclax

Tigit, CD226 and PD-L1/PD-1 Are Highly Expressed By Marrow-Infiltrating T Cells in Patients with Multiple Myeloma

Minimal Residual Disease (MRD) Assessment By Multiparametric Flow Cytometry Is Prognostic for Progression-Free Survival in Phase 1/1b Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients Treated with Idasanutlin MDM2 Antagonist

Mutation Load and a Functional T Effector Signature May Distinguish Immunologically Distinct and Clinically Relevant Lymphoma Subsets

Safety and Clinical Activity of Atezolizumab (Anti-PDL1) in Combination with Obinutuzumab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

KIR and HLA Genotypes Influence Clinical Outcome in Multiple Myeloma Patients Treated with SAR650984 (Anti-CD38) in Combination with Lenalidomide and Dexamethasone

Delayed Hematopoietic Recovery After Autologous Stem Cell Transplantation In Patients Receiving Arsenic Trioxide-Based Therapy For Acute Promyelocytic Leukemia

Natural Killer Cell Licensing Delineates NK “Helper/Repair” and NK “Effector/Suppressor” Subsets During Viral Infections

Donor KIR3DL1 and HLA-B Allotypes Control Leukemia Relapse After Allogeneic Hematopoietic Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only